依达拉奉联合20%人血白蛋白对危重脑出血患者NIHSS评分及血清cFN SAA表达的干预作用

doi:10.3969/j.issn.1006-6233.2021.02.009

摘要
图/表
参考文献
相关文章 (13)

全文: PDF (1222 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探究依达拉奉联合20%人血白蛋白对危重脑出血患者NIHSS评分及血清细胞纤维连接蛋白(cFN)、淀粉样蛋白A(SAA)表达的干预作用。方法: 对我院2017年8月至2019年10月126例危重脑出血患者进行回顾性分析,根据治疗方案不同分为观察组(n=42)、对照A组(n=42)、对照B组(n=42)。常规治疗基础上,对照A组采取依达拉奉治疗,对照B组采取20%人血白蛋白治疗,观察组采取依达拉奉联合20%人血白蛋白治疗,均治疗10d。比较三组疗效、不良反应与治疗前、治疗10d后颅内压、血肿体积、NIHSS评分、昏迷程度评分(GCS)、日常生活能力评分(BI)、血清cFN、SAA水平。结果: 观察组治疗10d后总有效率95.24%高于对照A组69.05%、对照B组80.95%(P<0.05);三组治疗10d后颅内压、血肿体积较治疗前降低,且观察组低于对照A组、对照B组(P<0.05);三组治疗10d后NIHSS评分较治疗前下降,且观察组低于对照A组、对照B组,GCS、BI评分较治疗前增高,且观察组高于对照A组、对照B组(P<0.05);三组治疗10d后血清cFN、SAA水平较治疗前降低,且观察组低于对照A组、对照B组(P<0.05);观察组、对照A组、对照B组不良反应发生率分别为16.67%、9.53%、7.14%,组间对比,差异无统计学意义(P>0.05)。结论: 依达拉奉联合20%人血白蛋白治疗危重脑出血患者,可促进血肿吸收,改善意识状态及神经功能,提高日常生活能力,降低血清cFN、SAA水平,疗效显著,且安全性高。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王路娜
	钱健
	杨光宇
	沙杜鹃

关键词 ：依达拉奉, 20%人血白蛋白, 重脑出血, 细胞纤维连接蛋白, 淀粉样蛋白A

Abstract：Objective: To investigate the effect of edaravone combined with 20% human albumin on NIHSS scores and serum cell fibronectin (cFN) and amyloid A (SAA) expression in patients with severe cerebral hemorrhage Methods: 126 patients with severe cerebral hemorrhage in our hospital from August 2017 to October 2019 were analyzed and divided into observation group (n = 42), control group A (n = 42) and control group B (n = 42). On the basis of conventional treatment, control group A was treated with edaravone, control group B was treated with 20% human albumin, and observation group was treated with edaravone combined with 20% human albumin, All were treated for ten days. The efficacy, adverse reactions, and intracranial pressure, hematoma volume, NIHSS score, Glasgow Coma Scale score (GCS), Barthel Index score (BI), serum cFN, and SAA levels were compared between the three groups before and after treatment. Results: The total effective rate in the observation group after treatment for ten days was 95.24%, which was higher than that of the control group A 69.05% and the control group B 80.95% (P<0.05). The intracranial pressure and hematoma volume of the three groups were reduced after treatment for ten days, and the observation group was lower than those in the control A and B groups (P<0.05). After ten days of treatment in the three groups, the NIHSS scores were lower than before treatment, and the observation group was lower than those in control group A and control B. The GCS and BI scores were higher than before treatment, and the observation group was higher than those in control group A and control group B (P<0.05). The serum cFN and SAA levels in the three groups were lower than those before treatment, and the observation group was lower than those in the control A and B groups (P<0.05). The incidences of adverse reactions in observation group, control group A and control group B were 16.67%, 9.53%, and 7.14%, and there was no significant difference between the groups (P>0.05). Conclusion: Edaravone combined with 20% of human albumin in the treatment of patients with severe cerebral hemorrhage can promote hematoma absorption, improve consciousness and nerve function, improve daily living ability, reduce serum cFN and SAA levels have significant efficacy and high safety.

Key words： Edaravone 20% human serum albumin Cerebral hemorrhage Cell fibronectin Serum amyloid A

基金资助:国家自然基金面上项目,(编号:81571122 );江苏省南京市医学科技发展项目,(编号:YKK17067)

通讯作者: 钱健

引用本文:

王路娜, 钱健, 杨光宇, 沙杜鹃. 依达拉奉联合20%人血白蛋白对危重脑出血患者NIHSS评分及血清cFN SAA表达的干预作用[J]. 河北医学, 2021, 27(2): 217-222.
WANG Luna, QIAN Jian, YANG Guangyu, et al. Interventional Effect of Edaravone Combined with 20% Human Albumin on NIHSS Scores and Serum cFN SAA Expression in Patients with Severe Cerebral Hemorrhage. HeBei Med, 2021, 27(2): 217-222.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2021.02.009 或 http://www.hbyxzzs.cn/CN/Y2021/V27/I2/217

[1] Abid KA,Sobowale OA,Parkes LM,et al.Assessing inflammation in acute intracerebral hemorrhage with PK11195 PET and dynamic contrast-enhanced MRI[J].Neuroimag,2018,28(2):158~161.
[2] Chang CF,Goods BA,Askenase MH,et al.Erythrocyte efferocytosis modulates macrophages towards recovery after intracerebral hemorrhage[J].Clin Invest,2018,128(2):607~624.
[3] 王二玲,石彦杰,刘晓刚,等.依达拉奉对脑出血患者早期血肿扩大及疗效的影响[J].医药导报,2017,36(11):1280~1282.
[4] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国脑出血诊治指南(2019)[J].中华神经科杂志,2019,52(12):994~1005.
[5] 王涛,于路,郭道骝,等.依达拉奉联合尼莫地平序贯疗法治疗脑出血的临床疗效及其对患者细胞免疫功能、神经功能的影响[J].实用心脑肺血管病杂志,2018,26(7):113~116.
[6] 买丽克·伊明,郑茜,古孜丽努尔·吐尼亚孜.醒脑静联合依达拉奉治疗高血压脑出血疗效及其可能的作用机制[J].内科急危重症杂志,2019,25(2):126~129.
[7] Li S,Wang L,Hao J,et al.Investigation of interaction between ozagrel and human serum albumin by spectroscopic and electrochemical methods[J].Appl Spectrosc,2017,83(6):1076~1083.
[8] 孙勇,范国峰,潘涛,等.颅内血肿微创清除术联合白蛋白治疗高血压性脑出血的临床观察[J].河北医药,2015,37(6):839~841.
[9] 李迪,李艳,彭锐.脑出血对患者血清中血清淀粉样蛋白A水平的影响[J].检验医学与临床,2017,14(3):350~351,354.
[10] Wang X,Wang J,Zhao H,et al. Clinical analysis and treatment of symptomatic intracranial hemorrhage after deep brain stimulation surgery[J].Br Neurosurg,2017,31(2):217~222.
[11] 李福雷,刘娜,张晓津,等.血清铁蛋白及细胞纤维连接蛋白在急性脑出血病人中的表达及其对预后评估的价值[J].实用老年医学,2018,32(6):583~584.
[12] 何金邦,赵晓萍,赵秀欣,等.老年脑出血患者血清cFN水平变化及其临床意义[J].脑与神经疾病杂志,2017,25(2):67~70.